COMPARATIVE ANALYSIS OF THE EFFECTS OF ROSUVASTATIN AND ATORVASTATIN ON THE SERUM LIPID PROFILE IN DIABETIC HEART PATIENTS
Main Article Content
Keywords
.............
Abstract
A condition of lipoprotein metabolism, hyperlipidaemia encompasses many disorders, including hypertriglyceridemia and hypercholesterolaemia. The World Health Organisation (WHO) recently said that by 2020, Indians will account for 60% of cardiovascular cases. The care of vascular disorders now includes the use of statins to treat hyperlipidaemia. The last five years have seen a significant expansion in statin indications due to the release of numerous multicenter prospective trials. The Indian market offers a variety of statins, including rosuvastatin, atorvastatin, simvastatin, pravastatin, pitavastatin, fluvastatin, and cerivastatin. Statins have a hypolipidemic impact because they inhibit hydroxymethylglutaryl-CoA reductase (HMG-CoA), and they lower LDL-C because they increase LDL receptor activation. This study's goal is to assess andThe World Health Organisation (WHO) recently said that by 2020, Indians will account for 60% of cardiovascular cases. The care of vascular disorders now includes the use of statins to treat hyperlipidaemia.
References
1. Wilson PW, Anderson KM, Castelli WP. Twelve-year incidence of coronary heart disease in middle-aged adults during the era of hypertensive therapy: the Framingham offspring study. Am J Med. 1991 Jan;90(1):11-6. doi: 10.1016/0002-9343(91)90500-w. Erratum in: Am J Med 1991 Apr;90(4):537. PMID: 1986576.
2. Kontopoulos AG, Athyros VG, Papageorgiou AA, Hatzikonstandinou HA, Mayroudi MC, Boudoulas H. Effects of simvastatin and ciprofibrate alone and in combination on lipid profile, plasma fibrinogen and low density lipoprotein particle structure and distribution in patients with familial combined hyperlipidaemia and coronary artery disease. Coron Artery Dis. 1996 Nov;7(11):843-50. doi: 10.1097/00019501-199611000-00009. PMID: 8993943.
3. Bakker-Arkema RG, Davidson MH, Goldstein RJ, Davignon J, Isaacsohn JL, Weiss SR et al. Efficacy and safety of a new
HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyc-eridemia. JAMA. 1996;275(2):128-33.
4. Bhopal R, Fischbacher C, Vartiainen E, Unwin N, White M, Alberti G. Predicted and observed cardiovascular disease in South Asians: application of FINRISK, Framingham and SCORE models to Newcastle Heart Project data. J Public Health (Oxf). 2005 Mar;27(1):93-100. doi: 10.1093/pubmed/fdh202. PMID: 15749725.
5. McKenney JM. Update on the National Cholesterol Education Program Adult Treatment Panel III guidelines: getting to goal. Pharmacotherapy. 2003 Sep;23(9 Pt 2):26S-33S. doi: 10.1592/phco.23.11.26s.32710. PMID: 14524636.
6. Bersot TP, Pépin GM, Mahley RW. Risk determination of dyslipidemia in populations characterized by low levels of high-density lipoprotein cholesterol. Am Heart J. 2003 Dec;146(6):1052-9. doi: 10.1016/S0002-8703(03)00516-7. PMID: 14660998
7. Topol EJ. Intensive statin therapy--a sea change in cardiovascular prevention. N Engl J Med. 2004 Apr 8;350(15):1562-4. doi: 10.1056/NEJMe048061. Epub 2004 Mar 8. PMID: 15007111.
8. Wang TD, Chen WJ, Lin JW, Cheng CC, Chen MF, Lee YT. Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: relations with baseline lipid profiles. Atherosclerosis. 2003 Oct;170(2):315-23. doi: 10.1016/s0021-9150(03)00296-x. PMID: 14612213.
9. Farnier M, Picard S. Diabetes: Statins, fibrates, or both. Curr Atheroscler Rep. 2001;3(1):19-28.
10. Cziraky MJ, Watson KE, Talbert RL. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting. J Manag Care Pharm. 2008 Oct;14(8 Suppl):S3-28; quiz S30-1. doi: 10.18553/jmcp.2008.14.S8-A.1. PMID: 19891279; PMCID: PMC10438150.
11. Jackevicius CA, Tu JV, Ross JS, Ko DT, Krumholz HM. Use of ezetimibe in the United States and Canada. N Engl J Med. 2008;358:1819–28. doi:10.1056/NEJMsa0801461. [DOI] [PubMed] [Google Scholar]
12. Guerin M, Egger P, Soudant C, Le Goff W, van Tol A, Dupuis R, Chapman MJ. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux. Atherosclerosis. 2002 Aug;163(2):287-96. doi: 10.1016/s0021-9150(02)00037-0. PMID: 12052475.
13. Kreisberg RA. Diabetic dyslipidemia. Am J Cardiol. 1998 Dec 17;82(12A):67U-73U; discussion 85U-86U. doi: 10.1016/s0002-9149(98)00848-0. PMID: 9915665.
14. Cholesterol Treatment Trialists’ (CTT) Collaboration; Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010 Nov 13;376(9753):1670-81. doi: 10.1016/S0140-6736(10)61350-5. Epub 2010 Nov 8. PMID: 21067804; PMCID: PMC2988224.
15. Kinlay S, Schwartz GG, Olsson AG, Rifai N, Leslie SJ, Sasiela WJ, et al. High dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes. Circulation
2003;26:571-81
16. Bairaktari ET, Tzallas CS, Tsimihodimos VK, Liberopoulos EN, Miltiadous GA, Elisaf MS. Comparison of the efficacy of atorvastatin and micronized fenofibrate in the treatment of mixed hyperlipidemia. J Cardiovasc Risk. 1999 Apr;6(2):113-6. doi: 10.1177/204748739900600208. PMID: 10353071.
17. Goel PK, Bharti BB, Pandey CM, Singh U, Tewari S, Kapoor A, Garg N, Sinha N. A tertiary care hospital-based study of conventional risk factors including lipid profile in proven coronary artery disease. Indian Heart J. 2003 May-Jun;55(3):234-40. PMID: 14560932.
18. Jones PH, Hunninghake DB, Ferdinand KC, Stein EA, Gold A, Caplan RJ, Blasetto JW; Statin Therapies for Elevated Lipid Levels Compared Across Doses to Rosuvastatin Study Group. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial. Clin Ther. 2004 Sep;26(9):1388-99. doi: 10.1016/j.clinthera.2004.09.006. Erratum in: Clin Ther. 2005 Jan;27(1):142. PMID: 15531001.
19. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001 May 16;285(19):2486-97. doi: 10.1001/jama.285.19.2486. PMID: 11368702.
20. Focus on hypertriglyceridemia: improving patient outcomes. J Am Acad Nurse Pract. 2007;19(12 Suppl 2):3. PMID: 18510280.
21. Talbert RL. Dyslipidemia. In: Diprio JT, editor. Pharmacotherapy-A Pathophysio- logical Approach. 8th ed. New York: McGraw-Hill; 2008. p. 365-88.
22. Tribble DL, Farnier M, Macdonell G, Perevozskaya I, Davies MJ, Gumbiner B, Musliner TA. Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia. Metabolism. 2008 Jun;57(6):796-801. doi: 10.1016/j.metabol.2008.01.026. PMID: 18502262.
23. Wierzbicki AS, Lumb PJ, Semra YK, Crook MA. High-dose atorvastatin therapy in severe heterozygous familial hypercholesterolaemia. QJM. 1998 Apr;91(4):291-4. doi: 10.1093/qjmed/91.4.291. PMID: 9666952.
2. Kontopoulos AG, Athyros VG, Papageorgiou AA, Hatzikonstandinou HA, Mayroudi MC, Boudoulas H. Effects of simvastatin and ciprofibrate alone and in combination on lipid profile, plasma fibrinogen and low density lipoprotein particle structure and distribution in patients with familial combined hyperlipidaemia and coronary artery disease. Coron Artery Dis. 1996 Nov;7(11):843-50. doi: 10.1097/00019501-199611000-00009. PMID: 8993943.
3. Bakker-Arkema RG, Davidson MH, Goldstein RJ, Davignon J, Isaacsohn JL, Weiss SR et al. Efficacy and safety of a new
HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyc-eridemia. JAMA. 1996;275(2):128-33.
4. Bhopal R, Fischbacher C, Vartiainen E, Unwin N, White M, Alberti G. Predicted and observed cardiovascular disease in South Asians: application of FINRISK, Framingham and SCORE models to Newcastle Heart Project data. J Public Health (Oxf). 2005 Mar;27(1):93-100. doi: 10.1093/pubmed/fdh202. PMID: 15749725.
5. McKenney JM. Update on the National Cholesterol Education Program Adult Treatment Panel III guidelines: getting to goal. Pharmacotherapy. 2003 Sep;23(9 Pt 2):26S-33S. doi: 10.1592/phco.23.11.26s.32710. PMID: 14524636.
6. Bersot TP, Pépin GM, Mahley RW. Risk determination of dyslipidemia in populations characterized by low levels of high-density lipoprotein cholesterol. Am Heart J. 2003 Dec;146(6):1052-9. doi: 10.1016/S0002-8703(03)00516-7. PMID: 14660998
7. Topol EJ. Intensive statin therapy--a sea change in cardiovascular prevention. N Engl J Med. 2004 Apr 8;350(15):1562-4. doi: 10.1056/NEJMe048061. Epub 2004 Mar 8. PMID: 15007111.
8. Wang TD, Chen WJ, Lin JW, Cheng CC, Chen MF, Lee YT. Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: relations with baseline lipid profiles. Atherosclerosis. 2003 Oct;170(2):315-23. doi: 10.1016/s0021-9150(03)00296-x. PMID: 14612213.
9. Farnier M, Picard S. Diabetes: Statins, fibrates, or both. Curr Atheroscler Rep. 2001;3(1):19-28.
10. Cziraky MJ, Watson KE, Talbert RL. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting. J Manag Care Pharm. 2008 Oct;14(8 Suppl):S3-28; quiz S30-1. doi: 10.18553/jmcp.2008.14.S8-A.1. PMID: 19891279; PMCID: PMC10438150.
11. Jackevicius CA, Tu JV, Ross JS, Ko DT, Krumholz HM. Use of ezetimibe in the United States and Canada. N Engl J Med. 2008;358:1819–28. doi:10.1056/NEJMsa0801461. [DOI] [PubMed] [Google Scholar]
12. Guerin M, Egger P, Soudant C, Le Goff W, van Tol A, Dupuis R, Chapman MJ. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux. Atherosclerosis. 2002 Aug;163(2):287-96. doi: 10.1016/s0021-9150(02)00037-0. PMID: 12052475.
13. Kreisberg RA. Diabetic dyslipidemia. Am J Cardiol. 1998 Dec 17;82(12A):67U-73U; discussion 85U-86U. doi: 10.1016/s0002-9149(98)00848-0. PMID: 9915665.
14. Cholesterol Treatment Trialists’ (CTT) Collaboration; Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010 Nov 13;376(9753):1670-81. doi: 10.1016/S0140-6736(10)61350-5. Epub 2010 Nov 8. PMID: 21067804; PMCID: PMC2988224.
15. Kinlay S, Schwartz GG, Olsson AG, Rifai N, Leslie SJ, Sasiela WJ, et al. High dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes. Circulation
2003;26:571-81
16. Bairaktari ET, Tzallas CS, Tsimihodimos VK, Liberopoulos EN, Miltiadous GA, Elisaf MS. Comparison of the efficacy of atorvastatin and micronized fenofibrate in the treatment of mixed hyperlipidemia. J Cardiovasc Risk. 1999 Apr;6(2):113-6. doi: 10.1177/204748739900600208. PMID: 10353071.
17. Goel PK, Bharti BB, Pandey CM, Singh U, Tewari S, Kapoor A, Garg N, Sinha N. A tertiary care hospital-based study of conventional risk factors including lipid profile in proven coronary artery disease. Indian Heart J. 2003 May-Jun;55(3):234-40. PMID: 14560932.
18. Jones PH, Hunninghake DB, Ferdinand KC, Stein EA, Gold A, Caplan RJ, Blasetto JW; Statin Therapies for Elevated Lipid Levels Compared Across Doses to Rosuvastatin Study Group. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial. Clin Ther. 2004 Sep;26(9):1388-99. doi: 10.1016/j.clinthera.2004.09.006. Erratum in: Clin Ther. 2005 Jan;27(1):142. PMID: 15531001.
19. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001 May 16;285(19):2486-97. doi: 10.1001/jama.285.19.2486. PMID: 11368702.
20. Focus on hypertriglyceridemia: improving patient outcomes. J Am Acad Nurse Pract. 2007;19(12 Suppl 2):3. PMID: 18510280.
21. Talbert RL. Dyslipidemia. In: Diprio JT, editor. Pharmacotherapy-A Pathophysio- logical Approach. 8th ed. New York: McGraw-Hill; 2008. p. 365-88.
22. Tribble DL, Farnier M, Macdonell G, Perevozskaya I, Davies MJ, Gumbiner B, Musliner TA. Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia. Metabolism. 2008 Jun;57(6):796-801. doi: 10.1016/j.metabol.2008.01.026. PMID: 18502262.
23. Wierzbicki AS, Lumb PJ, Semra YK, Crook MA. High-dose atorvastatin therapy in severe heterozygous familial hypercholesterolaemia. QJM. 1998 Apr;91(4):291-4. doi: 10.1093/qjmed/91.4.291. PMID: 9666952.
Article Sidebar
Published
May 20, 2024
Article Details
How to Cite
Dr Ashish Sharma, Dr Aaesha Khanam, Dr Manish Pokra, & Dr Ranu Suthar. (2024). COMPARATIVE ANALYSIS OF THE EFFECTS OF ROSUVASTATIN AND ATORVASTATIN ON THE SERUM LIPID PROFILE IN DIABETIC HEART PATIENTS. Journal of Population Therapeutics and Clinical Pharmacology, 32(10), 962-975. https://doi.org/10.53555/5qpn5803
Section
Articles
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Author Biographies
Dr Ashish Sharma
Assistant Professor,Dept. of Biochemistry, PIMS Medical College, Udaipur
Dr Aaesha Khanam
Senior Resident, Dept. of Obs. And Gynae.,Kota Medical College, Kota
Dr Manish Pokra
Assistant Professor, Dept. of Microbiology, RVRS Medical College, Bhilwara
Dr Ranu Suthar
PhD Scholar, Dept. of Physiology, Index Medical College,Indore
How to Cite
Dr Ashish Sharma, Dr Aaesha Khanam, Dr Manish Pokra, & Dr Ranu Suthar. (2024). COMPARATIVE ANALYSIS OF THE EFFECTS OF ROSUVASTATIN AND ATORVASTATIN ON THE SERUM LIPID PROFILE IN DIABETIC HEART PATIENTS. Journal of Population Therapeutics and Clinical Pharmacology, 32(10), 962-975. https://doi.org/10.53555/5qpn5803
